目的：探讨改良式青光眼Ahmed引流阀植入联合康柏西普玻璃体腔注射治疗新生血管性青光眼(NVG)的效果观察。

方法：前瞻性研究。将我院眼科2015-05/2018-05间临床诊断为NVG的患者59例60眼纳入研究，按照随机数字抽签法分为试验组和对照组，试验组20例21眼采取改良式青光眼Ahmed引流阀植入联合康柏西普玻璃体腔注射治疗； 对照组39例39眼采用单纯睫状体光凝治疗； 两组患者均术后随访观察3mo，比较两组患者术后眼压情况。

结果：两组患者术前资料对比无差异，在随诊观察3mo中均较术前眼压降低(P<0.05)，两组患者眼压在术后1wk，1、3mo有差异(均P<0.05)，术后1mo两组患者新生血管变化有差异(Z=2.74，P<0.05)。

结论：改良式青光眼Ahmed引流阀植入联合康柏西普玻璃体腔注射较单纯睫状体光凝在NVG中的应用价值高，降压效果持久。

METHODS: Neovascular glaucoma patients(59 cases, 60 eyes)were separated into experiment group(20 cases, 21 eyes)and control group(39 cases, 39 eyes)in our hospital from 2015 to 2018. Patients in the experiment group received Ahmed drainage valve implantation and intravitreal conbercept injection while patients in the control group were treated with ciliarybody photocoagulation. The visual acuity, intraocular pressure and iris neovessels were observed in 3mo after operation.

RESULTS: There was no significantly difference in the preoperative data between the two groups and both of them can decrease intraocular pressure(P<0.05). The intraocular pressure of experiment group was significantly lower than that of control group in 1wk, 1mo and 3mo after treatment(all P<0.05). The iris neovessels disappeared in experiment group, which was significantly different from that in control group(Z=2.74,P<0.05).

CONCLUSION: Modified Ahmed drainage valve implantation combined with intravitreal conbercept injection can effectively decrease the intraocular pressure for a long time and make the iris neovessels vanish.